

Express Mail No.
EF230793065US

Patents
XEN-001



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Bassil Dahiyat, et al.
Appln. No.: 10/082,671 **Confirmation No.: 8367**
Filed: February 22, 2002
For: USE OF NUCLEIC ACID LIBRARIES TO CREATE
TOXICOLOGICAL PROFILES
Group Art Unit: 1645
Examiner: Not Yet Assigned

New York, New York
May 17, 2002

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants hereby make of record the references listed in the accompanying Form PTO-1449. Copies of these references are enclosed.

It is respectfully requested that the Examiner (1) fully consider the enclosed references during the examination of this application; (2) initial the enclosed copy of Form PTO-1449 in the appropriate places to indicate that the references have been considered; and (3) return a copy of the initialed Form to the undersigned in accordance with MPEP §§ 609 and 2001.06(b).

Applicants have not yet received a substantive Examiner's Action. Therefore, pursuant to 37 C.F.R. § 1.97(b)(3), no fee is required in connection with this

Information Disclosure Statement. However, the Director is hereby authorized to charge any fees required in connection with this Information Disclosure Statement to Deposit Account No. 06-1075.

Respectfully submitted,



Z. Ying Li (Reg. No. 42,800)

Agent for Applicant

c/o FISH & NEAVE

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
XEN/001APPLN. NO.
10/082,671APPLICANT
Bassil Dahiyat et al.FILING DATE
February 22, 2002GROUP
1645INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Aardema et al., "Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "omics" technologies", <u>Mutation Research</u> , 499:13-25 (2002).
	Afshari et al., "Application of Complementary DNA Microarray Technology to Carcinogen Identification, Toxicology, and Drug Safety Evaluation", <u>Cancer Research</u> , 59:4759-4760 (1999).
	Altman et al., "Challenges for Biomedical Informatics and Pharmacogenomics", <u>Ann. Rev. Pharmacol. Toxicol.</u> 42:113-33 (2002).
	Bartosiewicz et al., "Development of a Toxicological Gene Array and Quantitative Assessment of this Technology", <u>Archives of Bio. and Biophysics</u> , 376:66-73 (2000).
	Burchiel et al., "Analysis of Genetic and Epigenetic Mechanisms of Toxicity: Potential Roles of Toxicogenomics and Proteomics in Toxicology", <u>Toxicol. Sci.</u> , 59:193-195 (2001).
	Dudley et al., "An Aryl Hydrocarbon Receptor Independent Mechanism of JP-8 Jet Fuel Immunotoxicity in Ah-Responsive and Ah-Nonresponsive Mice", <u>Toxic. Sci.</u> , 59:251-259 (2001).
	Haberkorn et al., "Functional genomics and proteomics-the role of nuclear medicine", <u>Euro. Journ. of Nucl. Med.</u> , 29:115-132 (2002).
	Isfort et al., "Toxicology for the Next Millenium", <u>Ann. of the NY Aca. of Sci.</u> , 919:48-51 (2000).
	Los et al., "Using mRNA Expression Profiling to Determine Anticancer Drug Efficacy", <u>Cytometry</u> , 47:66-71 (2002).
	Mancinelli et al., "Pharmacogenomics: The Promises of Personalized Medicine", <u>AAPS PharmSci</u> , 2(1) article 4.
	Nuwaysir et al., "Microarrays and Toxicology: The Advent of Toxicogenomics", <u>Molecular Carcinogenesis</u> , 24:153-159 (1999).
	Olden et al., "A Bold New Direction for Environmental Health Research", <u>Am. Journ. of Pub. Health</u> , 91:1964-1967 (2001).
	S. Ruepp et al., "Genomics and Proteomics Analysis of Acetaminophen Toxicity in Mouse Liver", <u>Toxicol. Sci.</u> , 65(1):135-50 (2002).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.